Invitae Aktie

Invitae EBITDA

Delisted·7. aug. 2024

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Invitae (NVTAQ) pr. 22. aug. 2026 er 175,45 Mio. USD. I foregående år var EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) -704,65 Mio. USD — en ændring på -124,90 % (højere).

EBITDA

175,45 Mio.USD

YoY

-124,90%

Senest opdateret:

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Invitae er 2026 175,45 Mio. USD. EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Invitae var 2025 -704,65 Mio. USD. Det falder dermed med -124,90% højere sammenlignet med året før.
Access this data via the Eulerpool API

Invitae Aktieanalyse

Hvad laver Invitae? Invitae Corp is a US-based company specialized in providing genetic tests for the diagnosis, treatment, and prevention of diseases. It was founded in 2010 and is headquartered in San Francisco, California. The company's goal is to lower the cost of genetic testing and increase accessibility for patients through automation and sample pooling methods. Invitae has received significant funding and has expanded its capital through multiple rounds of investments from venture capital firms, totaling nearly half a billion dollars. Its business model focuses on offering genetic tests to a wide range of patient groups, streamlining the testing processes through automation and software optimization. Invitae serves consumers directly, as well as medical professionals, hospitals, health centers, laboratories, and health insurance companies. The company aims to improve disease diagnosis and early detection while promoting long-term patient health. Invitae has broadened its capabilities through strategic acquisitions and partnerships, consolidating genetic data on a single platform. It offers a diverse portfolio of genetic tests for the diagnosis, treatment, and prevention of various diseases, including cancer predisposition, cardiovascular diseases, rare inherited diseases, neurological disorders, and medical genomics. The company also provides genetic counseling and family-oriented diagnosis services, along with an online platform facilitating interactive communication between doctors and patients, enabling the sharing and presentation of genetic information and test results. Invitae is an innovative company that has established itself as a market leader in genetic testing, offering a wide range of products and services facilitated by advanced technologies and data storage solutions. The recent acquisitions and partnerships have expanded Invitae's portfolio, improved its technology platform, and strengthened its position as a provider of high-quality healthcare services, enabling well-informed decision-making for patients and medical professionals. Invitae er et af de mest populære virksomheder på Eulerpool.com.

Hyppigt stillede spørgsmål om Invitae aktie

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Invitae er 175,45 Mio. USD i 2026.

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) for Invitae ændrede sig fra -704,65 Mio. USD til 175,45 Mio. USD, hvilket repræsenterer en ændring på -124,90 %. Værdien er højere end i foregående år.

På Eulerpool kan du finde den fuldstændige historiske udvikling af EBITDA (Indtjening før renter, skatter, af- og nedskrivninger) Invitae siden 2006 – med årlige værdier, diagrammer og detaljeret analyse.

EBITDA måler driftsresultatet før virkningen af finansieringsstruktur, skattesystem og ikke-kontante afskrivninger.

EBITDA = EBIT + Af- og nedskrivninger

EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s USD er en vigtig faktor for investorer. Ændringer i denne nøgletal kan signalere forbedrede eller forværrede fundamentale forhold, hvilket kan påvirke aktiekursen. På Eulerpool kan du følge EBITDA (Indtjening før renter, skatter, af- og nedskrivninger)s Invitae historisk.

Access this data via the Eulerpool API

Resultatopgørelse — Invitae

Alle nøgletal — Invitae